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Abstract
Identifying the young patient at risk of malignant arrhythmias and sudden cardiac death remains 
a challenge. It is increasingly recognised that sudden death, syncope and aborted cardiac arrest at 
a young age in patients with a structurally normal heart may be the result of various ion channel 
disorders - the channelopathies. The approach to risk stratification involves a combination of the 
clinical presentation, taken in conjunction with the family history, genetic testing, invasive 
electrophysiological studies or other provocative tests where appropriate and feasible. A logical 
approach to risk stratification in some of the commoner channelopathies seen in paediatric 
practice is presented. 
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Introduction
The recognition that several of the common causes of sudden arrhythmic death in young patients 
are the result of mutations affecting ion channels at the level of the individual cell (and hence the 
generic disease description of channelopathies) has led to increasing interest in genotyping. For 
clinical practice, it is of interest to investigate to what extent genotyping is of relevance in the 
management of an individual patient suspected or known to have a channelopathy, and to compare 
the results of such genetic testing with the use of clinical markers of risk for sudden death. We 
will provide a brief overview of the commoner symptomatic channelopathies which present in 
young   patients.                                                                                    
The   congenital   long   QT   syndrome                                                              
Since its initial clinical description, our knowledge of the disease entity, the cellular mechanisms 
that underlie the various forms of the disease (the number of different genotypes associated with 
the long QT syndrome is currently 12) and the association between specific genotypes and the risk 
of sudden death has expanded exponentially. The relationship between genotype and phenotype 
(the clinical expression of the disease) has been well studied. Initial studies focused on the specific 
ECG characteristics of the three commonest genotypes (LQTS types 1-3) which account for 
approximately 70% of patients with the long QT syndrome. Particularly in adult patients, the QT 
morphology was shown to be quite distinctive for each of these genotypes, although there are 
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substantial variations in repolarization abnormalities observed in the same subject and in members 
of the same family indicating both the dynamic nature of the disease and differences in gene 
penetrance [1-4]. Such relative specificity has also been observed for  triggers for cardiac events 
(syncope or sudden cardiac death) and the clinical course (age at onset of cardiac events and risk 
for aborted cardiac arrest or sudden cardiac death). In studies of genotype - phenotype correlation, 
it has been shown that arrhythmias were triggered primarily by exercise or emotional upset in 
LQTS1, by emotional upset and particularly sudden auditory stimuli in LQTS2, while arrhythmia 
occurred primarily at rest or during sleep in LQTS3 [5-7]. Swimming was found to be a 
particularly important trigger for ventricular arrhythmia in LQTS1 [6,8,9]. The genotype has also 
been demonstrated to be important in determining the incidence of cardiac events, from early 
studies arising from the international LQTS registry [10]. The risk of cardiac events has been 
shown to be significantly higher in LQTS 1 and LQTS2 when compared with LQTS3, with events 
occurring at a younger age. The cumulative mortality however was similar regardless of the 
genotype, as patients with LQTS3 had a higher percentage of potentially lethal events [10]. As 
will be seen, these early findings have to a large extent been reconfirmed by follow-up studies of 
the different age categories of patients in the LQTS registry.                                                 
Genotyping to assess risk of sudden death                                                                 
Knowing the specific mutation, or the location of the mutation has been shown to improve risk 
stratification. For LQTS 1, Shimizu et al demonstrated mutation site-specific differences in the 
risk of lethal arrhythmia in a Japanese population [11]. They showed that patients with mutations 
in the transmembrane domain of the KCNQ1 ion channel had more frequent cardiac events 
(syncope, aborted cardiac arrest or sudden cardiac death) than patients with C-terminal mutations. 
They also had a greater risk of the first cardiac event occurring at a younger age. Several baseline 
ECG parameters affecting cardiac repolarization (Q-Tend, Q-Tpeak, Tpeak-end intervals) were 
also significantly longer in subjects with transmembrane mutations, with exaggerated response of 
some of these measures (Q-Tend and Tpeak-end) to sympathetic stimulation. The differences in 
the dynamic response of ventricular repolarization to sympathetic stimulation between the 3 main 
genotypes (LQT1 to 3) had already been previously established by Noda et al, who showed that 
the QTc was maximally prolonged as the RR interval decreased in LQTS1 patients, moderately 
prolonged in LQTS2 patients, and least prolonged in LQTS3 patients in response to intravenous 
epinephrine [12]. They speculated, justifiably, that this difference in the dynamic response of 
ventricular repolarization to sympathetic stimulation may explain why the trigger for cardiac 
events differs between the genotypes. Moss et al demonstrated that patients with transmembrane 
mutations were at increased risk of cardiac events compared with those with C-terminus 
mutations. In addition, the biophysical function of the mutation was also important in determining 
the phenotype. Patients with a dominant negative effect of the mutation on ion channel function 
(>50% reduction in function) had a more severe phenotype compared with those exhibiting 
haploinsufficiency (< or = 50% reduction in IKs potassium channel current) [13].  These genetic 
risks were independent of traditional clinical risk factors such as the manifest QTc interval on the 
ECG, suggesting that variability in the electrophysiologic effects of the different mutations 
contributes to the variability in the risk of life-threatening cardiac events [14]. This in turn 
suggests that it is not sufficient to know the genotype, but knowledge of the specific mutation and 
its biophysical function is essential for risk stratification. For LQTS2, similar genotype-phenotype 
correlations have been established. It has been shown that subjects harbouring pore mutations 
have a more severe clinical course and a higher frequency of arrhythmic events occurring at a 
younger age when compared with those with nonpore mutations [15]. In a more recent study, 
missense mutations in the transmembrane pore (S5-loop-S6) region were associated with the 
highest risk  of  clinical  arrhythmia  [16].  Further  studies  involving the  US,  Japanese  and 
Netherlands LQTS registries are currently underway to further analyse risk associated with 
specific mutations in the HERG gene.  Preliminary data for LQTS3 subjects with SCN5A sodium 
channel mutations also suggest that the location of the mutation and its biophysical function may 
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be important determinants of the clinical phenotype [17-19], although further data from the 
combined LQTS registries are awaited.                                                                                 
Even more interestingly, and further supporting the case for detailed genetic studies as part of the 
diagnostic work-up in assessing risk, it has been shown that specific mutations are associated with 
unusual clinical severity. The KCNQ1-A341V mutation was shown in a founder population in 
South Africa to have a severe phenotype [20]. While the QTc (if >500 ms) also affected the 
phenotypic expression, when matched for QTc with LQT1 database patients, the presence of a 
KCNQ1- A341V mutation was still associated with a larger probability of experiencing a cardiac 
event. Additional studies on subjects from different ethnic backgrounds have confirmed the 
unusual clinical severity associated with the KCNQ1-A341V mutation, suggesting that mutation-
specific behaviour exists independent of ethnic or genetic background. The KCNQ1-A341V 
mutation carriers were more likely to have cardiac events at a younger age, and also had a longer 
QTc [21].  Given the wide variations in QTc in individuals carrying the same mutation, it is also 
evident that additional genetic or environmental influences play a role in modifying both the QTc 
and the risk of sudden death. A lower resting heart rate has been shown to be protective, 
suggesting that individual autonomic make-up modulates phenotypic expression [22,23]. Whether 
a blunting of the autonomic response in individual subjects (conferring a protective effect) may be 
affected by specific adrenergic gene receptor polymorphisms has been the subject of subsequent 
investigations [23]. The clinical phenotype is not completely explained by the electrophysiologic 
effects or biophysical properties of the mutation, which has been shown to have a dominant 
negative effect on IKs. In the absence of detailed information on possible modifier genes, 
identification of the specific mutation alone is therefore insufficient in predicting individual risk. 
Other modifier genes which affect the severity of clinical expression of LQTS have been 
subsequently identified. These may vary from coinheritance of two independent mutations, either 
of which when inherited alone have a mild phenotype but when present in combination produce 
severe clinical manifestations [24], to the association of LQTS mutations with certain single 
nucleotide polymorphisms, occurring with varying degrees of frequency in the general population 
but   which   in   combination   produce   a   severe   clinical   phenotype   [25-27].                      
Specific single nucleotide polymorphisms, often occurring commonly in specific populations, 
have also been associated with a higher incidence of arrhythmic events and sudden death. The 
S1103Y polymorphism in the SCN5A gene is present in between 10 to 13% of healthy African 
Americans, and is the result of a single nucleotide substitution of a cytosine (c) for an alanine (a) 
in the second position of codon 1103, resulting in an amino acid change (serine for tyrosine in 
amino acid position 1103). It is associated with a markedly increased risk of arrhythmias in 
unrelated African American adults with arrhythmias [28], with QTc prolongation and syncope, 
and with an eightfold increase in the risk for sudden arrhythmic death in young African Americans 
[29]. It is also overrepresented in the sudden infant death syndrome, and in autopsy-negative 
sudden unexplained death in subjects older than 1 year in this specific population [30,31].
To summarise, the established yield of genetic testing in clinically irrefutable cases of LQTS is 
high [32]. There remains however, a considerable chance that a positive genetic test is a  false 
positive, and this is to some extent ethnicity dependent. In turn, this also means that as the clinical 
probability of LQTS decreases the probability that an identified mutation is non-causative 
correspondingly increases [33]. The nature of the mutation (nonsense, frameshift, splice-mutations 
or missense mutations) and the location of the mutation will all affect pathogenicity. The role of 
additional modifier genes in determining phenotypic expression in different individuals with an 
identical mutation also needs further elucidation.                                                                 
Clinical risk stratification in the LQTS                                                   
Several studies in the different age categories have been made possible by the establishment of 
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various LQTS registries. This has in turn made possible risk assessment for SCD/ACA (sudden 
cardiac death/aborted cardiac arrest) events based on several clinical and ECG criteria. Some of 
these will now be briefly described.                                                                               
The risk factors for a cardiac event during the first 12 months of life (SCD/ACA/syncope) include 
a QTc ≥ 500, a resting heart rate of ≤ 100 beats/minute, and female sex. The risk for a subsequent 
SCD/ACA remains high, as established during a 10 year follow-up of this subset of patients, and 
beta-blocker therapy is only partially protective [34]. This has also been borne out by observations 
in other studies with shorter duration of follow-up [35]. Bradyarrhythmia (sinus bradycardia or 
functional 2:1 AV block) are also common in this population [36]. Long QT syndrome patients 
who experience potentially lethal clinical events in the first year of life are at high risk for similar 
events in the first decade of life, and additional therapies such as permanent pacing, left cardiac 
sympathetic denervation or early implantation of a defibrillator need to be considered on an 
individual basis. There is also an association between long QT syndrome and sudden infant death 
syndrome (SIDS), and routine newborn ECG screening has been advocated to identify infants at 
risk [37]. A detailed description of the risks and benefits of such an approach are beyond the scope 
of this review, but may be found in the following reviews [38,39]. It is to be anticipated however 
that routine ECG screening of siblings and other close family members of the index patient 
presenting in infancy will be more routinely undertaken, resulting in early identification of 
potentially affected, but as yet asymptomatic, individuals. Whether early institution of beta blocker 
therapy in individuals thus identified will be protective, is at present unknown. Sudden death of a 
sibling (at any age) has been thought to be associated with a higher risk of death in the LQTS 
population. This has however not been confirmed in an LQTS registry study of first- and second-
degree relatives of probands. Sibling death was not significantly associated with  increased risk of 
SCD/ACA; instead, the risk of adverse events in relatives was determined more by individual risk 
factors which included a QTc ≥530, a history of syncope, and gender [40]. QTc was highly 
predictive of ACA/SCD. A personal history of syncope, particularly if syncope had occurred 
within 2 years, was also strongly associated with ACA/ death. The effect of gender was time-
dependent. The risk of ACA/death/any cardiac event was higher in boys than in girls at a young 
age, but this relationship changed from late adolescence onwards, when women had a higher risk 
than men [40]. To conclude, severe symptoms in a close relative cannot be used as an indicator of 
personal risk for other family members who may have the same genotype, although such subjects 
are more likely to be treated with beta blockers from a young age [40].                                          
In children aged 1 to 12 years, boys were at a significantly increased risk of ACA/SCD. The risk 
factors for boys included a QTc>500 and prior syncope (with recent syncope within the previous 2 
years carrying a higher risk) whereas prior syncope (recent syncope being more risky than remote 
syncope) was the only significant risk factor in girls [41]. Routine beta blocker therapy was clearly 
protective, and was associated with a significant reduction in the risk of life-threatening cardiac 
events in this age group. Regardless of genotype, a family history of SCD did not predict a higher 
risk of cardiac events in childhood. Similar considerations apply to the adolescent population (aged 
between 10 and 20 years). Syncope (both timing of syncope and number of syncopal events) was a 
significant risk factor for predicting ACA/SCD, with recent (within the last 2 years) syncope and 
higher number of syncopal events during this period carrying a higher risk [38]. A QTc ≥530 was 
associated with increased risk. The effect of gender was age-dependent, with boys at higher risk in 
the age category 10-12 years, and no significant difference in gender-related risk being observed 
between 13 and 20 years [42]. The predominance of life-threatening events in boys during 
childhood and early adolescence may be the result of environmental (increased sport participation/ 
intensive physical activity), hormonal (opposing effects of estrogens and androgens on ventricular 
repolarization) or genetic (modifier genes not shared by boys and girls) influences [42]. Data on the 
specific genotype (LQTS1 vs LQTS2 vs LQTS3) did not contribute significantly to the outcome, as 
syncope was not used as one of the cardiac end-points unlike previous genotype based studies, but 
rather   as   a   time-dependent   covariate   to   assess   the   end   points   of   ACA/SCD   [10,42]. 
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Beyond 40 years of age, women with a QTc ≥470 are at a higher risk of SCD/ACA, while in men 
event rates were similar in the various QTc categories unaffected (QTc<449), borderline (QTc 440 
to 469) and electrocardiographically affected (QTc ≥470). Recent (<2 years in the past) syncope 
was the predominant risk factor in affected subjects, and those with a positive mutation had a 
significantly higher mortality, particularly those with an LQT3 mutation [43]. After the age of 60 
years, the risk of death due to LQTS competes with other disease entities which may lead to death. 
Even in this older population, a trend towards lower mortality was observed in patients treated 
with beta blockers, although this may have been the result of multiple protective mechanisms. 
Timely ICD implantation should obviously be considered in high risk patients remaining 
symptomatic despite beta blocker treatment.                                                                                      
The long QT syndrome in patients with other phenotypic anomalies                                      
Patients with associated phenotypic manifestations (Jervell and Lange-Nielsen syndrome in its 
homozygous  or  compound  heterozygous  state  and  associated  with sensorineural  deafness, 
Timothy syndrome which manifests skeletal abnormalities, syndactyly, structural heart disease, 
autism and immune deficiency with predisposition to sepsis usually have more severe clinical 
forms of the congenital long QT syndrome. Especially with the J and L-N and Timothy 
syndromes, they are also less likely to respond to beta blocker therapy alone, and early 
defibrillator implantation appears to be mandated in this population [44,45]. The QTc (if ≥550) 
and a history of syncope during the first year of life appear to be predictive of the degree of risk in 
individual patients with the Jervell and Lange-Nielsen syndrome  [44,46]. In contrast, the 
Anderson-Tawil  syndrome which may be associated with dysmorphic features, periodic paralysis 
and propensity for ventricular arrhythmias (PVCs and bidirectional ventricular tachycardia rather 
than torsade de pointes), has a generally more benign clinical course in terms of arrhythmic death 
[47]. The majority of these syndromes may be suspected from the presence of these characteristic 
clinical findings, and appropriate therapy decided upon.                                                                   
Do we need to know the genotype when selecting therapy?                                          
The arguments against routine genotyping for risk stratification and for selecting therapy in 
patients with long QT syndrome can be made on several grounds [48]. As seen above, clinical risk 
stratification is quite effective, when one considers the clinical presentation (syncope/ACA versus 
no symptoms) in combination with the QTc (if >500) [49,50]. The demographics of LQTS have 
also changed remarkably, with increased awareness of the disease and consequent early diagnosis. 
Unlike   the   view   held   prior   to   genotyping   and   the   establishment   of   genotype-phenotype 
correlations, LQTS is associated with a low rate of SCD/ACA, and the majority of patients are 
asymptomatic carriers. A significant proportion of phenotypically affected patients and their 
families cannot be identified at present by genetic screening alone, and given the varied clinical 
expression of symptoms (and QTc) in different family members carrying the same genetic 
mutation, therapy and clinical risk stratification cannot be standardised based on the identification 
of a specific mutation. Most importantly, there are only a limited number of therapies available 
which may prevent sudden arrhythmic death (beta blockers, ICD implantation, and probably 
selective left cardiac sympathetic denervation). Beta blockers have been shown to be highly 
effective (given appropriate patient compliance) for LQTS 1 and LQTS2, and for the subset of 
LQTS3 patients who have clinical events mediated by excessive adrenergic stimulation [51]. It 
seems reasonable therefore to recommend routine beta blocker therapy in all patients with the 
clinical diagnosis of LQTS, without knowledge of the genotype. The majority of LQTS3 patients 
(who form a small subset of the entire LQTS population) without adrenergic mediated events 
remain asymptomatic well into adult life, and perhaps do not require routine prophylactic therapy. 
The ICD may therefore be reserved for patients with persistent symptoms (recurrent syncope) 
despite beta blocker therapy, and those presenting with ACA. Data from children obtained in the 
era of ICD implantation tend to confirm these observations [50]. Early identification of the disease 
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and appropriate beta blocker therapy in combination with necessary physical restrictions and 
avoidance of QT prolonging medications (comprehensive lists of such drugs may be found on 
several websites such as www.azcert.org and www.Torsades.org) may all play a role in reducing 
mortality. Efficacy of beta blockade may require additional investigations such as exercise testing 
or epinephrine challenge [53,54]. There are even data suggesting that the differential response to 
epinephrine provocation helps to distinguish between the three major LQTS genotypes, allowing 
the application of presumptive genotype-specific treatment strategies [55]. While the current 
clinical practice tends to favour ICD implantation in young patients with a proven LQTS3 
genotype, there is no evidence at present that this aggressive approach is warranted if the majority 
of LQTS3 patients remain asymptomatic well into their 40s.                                        
The Brugada syndrome in paediatric practice                                                  
Risk stratification in adults with the Brugada syndrome has been extensively investigated [56-60]. 
In contrast, risk stratification in children is hampered by several factors. The disease is rare in 
large segments of the world's population; it often does not manifest clinically in childhood, and in 
the absence of a positive family history, identification of the index case in childhood can be 
difficult. Genetic testing provides a positive result in only approximately 30% of patients with the 
clinical phenotype of Brugada syndrome. While the ajmaline (or flecainide) tests have been used 
to identify patients who might have Brugada syndrome, a positive test does not predict the risk of 
future clinical events, and routine testing in childhood in asymptomatic individuals has generally 
not found favour, except in instances where there is an adverse family history and a negative 
genetic study, and where the parents are anxious to know whether their offspring has the disease 
[61,62]. Finally, therapeutic options, even after confirmation of the clinical phenotype by 
provocative tests, are limited.                                                                                              
Data on Brugada syndrome in children, apart from small case series or single reports are 
predominantly limited to a single multicenter study [63,64]. Thirty children aged <16 years were 
identified from 13 participating centers. All of them had a type 1 ECG either at rest or following 
drug challenge, with 10/11 symptomatic patients having a spontaneous type 1 ECG. In contrast to 
adult data, there was no male preponderance in this population (again not unexpected, as one 
would expect the sex hormones to have an unimportant role in this predominantly pre-pubertal 
population), and supraventricular arrhythmias were quite common. Episodes of syncope or SCD 
were also commonly associated with fever, emphasising the importance of rapid antipyretic 
therapy in this population. It has been shown in several studies that there are temperature-
dependent modifications in sodium channel properties, which may underly the propensity for 
atrial or ventricular arrhythmias; the reason why this is particularly so in children is as yet unclear 
[65,66]. Brugada syndrome was also present in at least 1 family member in 25/30 (83%) of 
children (including a family history of sudden death in 10/25 children). However, a family history 
of sudden death did not predict an adverse outcome, with the majority of children with a family 
history of SCD being asymptomatic at the time of assessment. Being a highly selected population, 
there was, not unexpectedly, also a high incidence of SCN5A mutations. Apart from the 
association of potentially life-threatening events with fever, the study also suggested that 
quinidine might be effective in preventing potentially lethal arrhythmias in children, and might 
even be considered as a bridge to eventual ICD implantation.                                        
Risk stratification in children with Brugada syndrome                                         
Provocative  testing                                                                                               
While drug testing may help to establish the diagnosis of Brugada syndrome, there are no data to 
show that a positive drug test alone, using either ajmaline or flecainide correlates with symptoms 
or with risk of sudden death. Exercise testing plays no role in risk stratification, as the majority of 
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syncopal or sudden death events occur at rest. The role of invasive EP study is similarly 
controversial. Based on meta-analyses of large adult studies, the role of routine EP testing for the 
purpose of risk stratification has generally been abandoned. It is however as yet unclear (apart 
from the possibility of a selection bias towards more severe cases in the series reported by the 
Brugada brothers) why there is such a discrepancy between their data and other studies [67-70]. 
There is general consensus that a negative EP study has a good negative predictive value, 
particularly   in   previously   asymptomatic   individuals   [67].   The   majority   of   asymptomatic 
individuals   with   a   negative   EP   study   (non-inducibility   of   ventricular   arrhythmia)   remain 
asymptomatic at follow-up. We have largely abandoned invasive EP studies in young children 
with a positive family history of Brugada syndrome, as these have invariably been negative. Our 
standard EP protocol for these patients has been to pace from 2 right ventricular sites, with upto 3 
extrastimuli with a minimum coupling interval of 200ms; it may be argued that this protocol is not 
aggressive enough, and that stimulation of epicardial sites also needs to be considered. To date 
however, we have had no inducible VT using this protocol, and none of the children has died 
suddenly or had a documented ventricular arrhythmia at follow-up. At present, we are implanting 
loop recorders (ILRs) in patients with a positive family history (where a family member has either 
died suddenly or has an ICD) who present with unexplained syncope. Despite this approach, we 
have not identified any child with ventricular arrhythmias documented by the ILR, where syncope 
was the presenting complaint. This suggests that syncope is common in the young population, and 
is in the majority of children unrelated to potentially lethal tachyarrhythmias.                   
 
Genetic testing                                                                                                                         
The cardiac sodium channel is the main determinant of impulse formation and propagation in the 
heart, and loss of function SCN5A mutations, with consequent slowing of cardiac conduction 
velocities result in the Brugada syndrome [71]. Other rare mutations involving the genes encoding 
subunits of the L-type calcium channel may also result in this clinical phenotype [72]. Currently, 
more than 100 mutations in 7 different genes have been associated with the Brugada syndrome 
[73]. Genotype-phenotype correlations in the Brugada syndrome have been less well investigated 
because only approximately 30% of patients with the clinical phenotype have a positive genotype, 
suggesting the possibility of genetic heterogeneity. It is recognised however that patients with 
established SCN5A mutations may have a higher incidence of resting ECG abnormalities and a 
larger increase in QRS duration following the administration of sodium channel blockers [74]. 
The PQ and QRS intervals in lead V2 were also more markedly prolonged with aging in the 
SCN5A   mutation-positive   group   during   follow-up   [75].   Histological   studies   also   showed 
significant apoptosis in the ventricular myocardium in patients with SCN5A mutations, suggesting 
further that abnormal sodium channel function may result in cellular damage, and an increased 
risk for arrhythmic events [76]. More recently, there has been preliminary evidence to suggest that 
the type of SCN5A mutation (missense mutations M -  in which a single amino acid is replaced by 
an aberrant one versus premature truncations - T mutations  - where the sodum channel protein is 
truncated because of the presence of a premature stop codon) and the degree of reduction in INa 
may have an effect on the phenotype [77]. The proportion of patients who experienced syncope 
(presumed to be arrhythmic in origin) was higher in those with a T mutation than those with an M 
mutation, as was the proportion of families in whom SCD had occurred in a first degree family 
member at a young age. Even among the M mutations, the clinical phenotype was more severe in 
patients with more severe INa reduction (M mutations with >90% peak INa reduction versus M 
mutations with ≤90% INa reduction).  Further evidence of the potential clinical importance of 
genotyping is provided by the knowledge that specific SCN5A mutations are associated with a 
high   risk   of   sudden   death   in   selected   populations   [78].   Certain   ethnic-specific   gene 
polymorphisms may also affect the clinical expression of the disease, although it is at present 
unlikely that this information can be incorporated into clinical practice [79,80].                       
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Clinical risk stratification
The presence of a spontaneous type 1 ECG (usually recorded in the context of symptoms such as 
syncope or aborted cardiac arrest in the individual, or when the patient presents for routine 
screening with a positive family history of Brugada syndrome) appears to be the only reliable 
marker for possible adverse arrhythmic events. As the ECG can vary on a daily basis, it is 
important therefore to undertake routine clinical follow-up, and obtain 12 lead ECG recordings 
every 6 months in asymptomatic individuals. Where a type 1 ECG occurs in combination with 
symptoms the treatment pathways become clearer; ACA=ICD; syncope=quinidine ± ILR ± ICD. 
What to do in the presence of a spontaneous type 1 ECG in an asymptomatic individual is 
controversial. Adult studies have shown that there is a near-equal distribution of a type 1 ECG 
between   symptomatic   and   asymptomatic   subjects   [57,59].   Further   developments   in   our 
understanding of the genetics of the disease may help in risk stratification. In selected patients 
with adverse family histories, prophylactic oral quinidine therapy may be considered [81,82]. It is 
also important in such patients to avoid drugs that have been reported to induce the type 1 ECG 
and/or fatal arrhythmias. A list of these, and current recommendations concerning their use, may 
be found at www.BrugadaDrugs.org [83]. A variety of additional ECG markers have been 
identified, which are associated with an increased risk of ventricular arrhythmias. These include 
daily fluctuations in the standard and signal averaged ECGs [84], prolonged QRS interval in V6 of 
≥ 90ms and prolonged r-J interval in V2 of ≥ 90ms [85]), fragmented QRS complexes [86,87], late 
potentials on signal-averaged ECGs [88,89], spontaneous changes in ST segments on continuous 
or multiple ECG recordings [90], and increased  Tpeak-Tend duration and Tpeak-Tend dispersion 
[91]. The clinical utility of these parameters in general practice remains to be established.    
Data from adult patients in whom ICDs have been implanted confirm that there is a low incidence 
of arrhythmic events at follow-up [92]. There is also a significant risk of device-related 
complications (approximately 9% per year), and it has been reconfirmed that recurrent syncope 
can occur in this population also in the absence of arrhythmia. In contrast to previous studies 
which suggested a good negative predictive value for EP studies, ICD follow-up data also show 
that the EP study may be limited even in this predictive function. The ICD however is protective, 
and none of the patients with an ICD died during follow-up [92].                                     
Catecholaminergic polymorphic ventricular tachycardia (CPVT)                            
Genetic   aspects                                                                                
Familial forms account for between 30 and 50% of  CPVT, with both autosomal dominant and 
recessive forms having been recognised (dominant ryanodine RyR2 receptor gene defect – CPVT1 
- and recessive calsequestrin 2 –CPVT2 - gene defects) [93,94].  The RyR2-encoded ryanodine 
receptor gene, mutations of which cause CPVT type 1 (CPVT1) is a relatively large gene, with 
mutations having been identified in up to 45 of of the 105 translated exons. Despite this large gene 
size, up to 65% of CPVT1-positive mutations can be discovered by selective analysis of 16 exons, 
which makes a tiered approach to genetic diagnosis feasible [95].                                        
Clinical   presentation                                                                                  
The syndrome has its clinical onset at a young age, and is characterised by ventricular arrhythmias 
occurring during exercise, typically when the heart rate exceeds a threshold value of between 120 
and 130/minute [96]. The initial presentation may be syncope, epileptic seizures secondary to 
ventricular arrhythmia and cerebral hypoxemia (which are often misdiagnosed as primary 
epileptic seizures), or sudden death. The disease is associated with a high mortality, with 30 to 
35% of patients with the clinical disease dying before the age of 30 years. There is also often a 
strong family history of syncope or sudden death, occurring in upto 30% of patients [96]. Akin to 
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LQTS1, ventricular arrhythmias may also be triggered during swimming, and CPVT1 causing 
RyR2 mutations were identified in up to 90% of patients with swimming-triggered arrhythmic 
events who were lacking sufficient clinical evidence for the diagnosis of LQTS [97]. RyR2 gene 
mutations  have  been identified at post-mortem in young  individuals dying  suddenly and 
unexpectedly [98,99] even when death occurred at rest, and may also be causal in a small 
proportion of sudden infant death syndrome [100]. This emphasises the importance of obtaining a 
genetic diagnosis where possible even after death, so that surviving relatives may be appropriately 
investigated   and   treated   [101].                                                                          
Risk   stratification                                                                                
The resting ECG is normal, and invasive EP studies have no role. Diagnosis, risk stratification and 
therapy are all guided by the clinical presentation in the individual, and by the family history 
(sudden unexplained death in a first degree relative, or established diagnosis in a family member). 
Therapy consists of avoidance of exercise and beta blocker therapy. The response to beta-blockers 
is variable, and additional measures are often necessary [102,103]. In patients with persistent 
symptoms additional therapeutic approaches include the addition of a calcium channel blocker 
[104], selective left sided cardiac sympathetic denervation [105,106] and/or implantation of an 
ICD   [107,108].                                                                              
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